{"id":231918,"date":"2026-02-23T13:18:40","date_gmt":"2026-02-23T19:18:40","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/sglt2-inhibitors-and-cardiorenal-outcomes-in-t2d-with-liver-cirrhosis"},"modified":"2026-02-23T13:18:40","modified_gmt":"2026-02-23T19:18:40","slug":"sglt2-inhibitors-and-cardiorenal-outcomes-in-t2d-with-liver-cirrhosis","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/sglt2-inhibitors-and-cardiorenal-outcomes-in-t2d-with-liver-cirrhosis","title":{"rendered":"SGLT2 Inhibitors and Cardiorenal Outcomes in T2D With Liver Cirrhosis"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/sglt2-inhibitors-and-cardiorenal-outcomes-in-t2d-with-liver-cirrhosis2.jpg\"><\/a><\/p>\n<p>Among adults with Type2Diabetes and liver cirrhosis, SGLT2 inhibitor use was associated with lower risks of end-stage kidney disease, cardiovascular events, mortality, and hepatic decompensation compared with DPP4 inhibitors.<\/p>\n<hr>\n<p>Importance Type 2 diabetes (T2D) and liver cirrhosis frequently coexist, creating a high-risk population for adverse outcomes. Patients with both conditions face elevated risks of kidney and cardiovascular complications, yet evidence regarding optimal antidiabetic therapy in this vulnerable population remains limited.<\/p>\n<p><strong>Objective<\/strong> To evaluate the association of sodium-glucose cotransporter\u20132 inhibitor (SGLT2i) vs dipeptidyl peptidase\u20134 inhibitor (DPP4i) use with kidney outcomes, cardiovascular events, and hepatic decompensation in patients with concurrent T2D and liver cirrhosis.<\/p>\n<p><strong>Design, Setting, and Participants<\/strong> This nationwide retrospective cohort study utilized data from the Taiwan\u2019s National Health Insurance Database between May 2016 and December 2023. Adults with both T2D and liver cirrhosis who initiated either SGLT2is or DPP4is were included.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Among adults with Type2Diabetes and liver cirrhosis, SGLT2 inhibitor use was associated with lower risks of end-stage kidney disease, cardiovascular events, mortality, and hepatic decompensation compared with DPP4 inhibitors. Importance Type 2 diabetes (T2D) and liver cirrhosis frequently coexist, creating a high-risk population for adverse outcomes. Patients with both conditions face elevated risks of kidney [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495],"tags":[],"class_list":["post-231918","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=231918"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231918\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=231918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=231918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=231918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}